What happened with CBLL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
CeriBell helps hospital clinicians check acute-care patients for seizures by recording and analyzing their brain waves. Its Ceribell System combines disposable headbands or headcaps with a pocket-sized recorder. Clarity, its AI-powered software, identifies potential seizure activity, while a web portal lets neurologists review recordings remotely in real time. The system supplements rather than replaces conventional brain-wave monitoring, known as EEG.
Hospitals and medical groups pay CeriBell directly. They buy single-patient-use Wearables separately and subscribe to Clarity, recorder access and the portal. CeriBell also sells recorders separately. Product sales provide most revenue, with subscriptions supplying a smaller recurring stream. Revenue depends on how many hospitals remain active customers and how often they use Wearables to evaluate patients.
Almost all revenue comes from U.S. healthcare providers. These customers recover the system’s cost within payments for patient care rather than having CeriBell bill insurers directly, so insurance coverage and reimbursement influence demand. CeriBell’s commercialized devices have FDA clearance; new devices, new uses and significant changes generally require further FDA authorization before marketing.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Ceribell’s results hinge on hospital adoption and use of its disposable Wearables against conventional and rapid-EEG competitors Natus, Nihon Kohden and Zeto, none of which appears in this list.
Hyperfine and Ceribell both depend on hospitals adopting more accessible bedside brain diagnostics: Hyperfine sells portable MRI scanners, initially focused on critical care, while Ceribell sells portable EEG systems for acute-care seizure monitoring. Watch Hyperfine’s Swoop system sales to U.S. hospitals as a sign of uptake of bedside diagnostics, rather than a direct measure of demand for Ceribell’s seizure monitoring.
CeriBell, Inc. earningsThis company
Ceribell charges hospitals for system access and sells disposable Wearables for each patient use, so this report will show whether subscriptions and use are growing together.
Read subscription revenue alongside product revenue. Subscription revenue reflects hospital access to Clarity and related services; product revenue mainly comes from disposable Wearables and moves with active accounts and patient use. Growth in both would show that hospitals are adding subscriptions and using more Wearables. Subscription growth with flat or falling product revenue would mean access is expanding without more patient use; weakness in both would point to pressure on adoption or retention.
Hyperfine, Inc. earningsHYPR
Hyperfine’s report will show whether U.S. hospitals are taking up its Swoop portable MRI system, a signal about the bedside brain-diagnostics market Ceribell sells into, not a direct measure of demand for Ceribell’s EEG monitoring.
Look for whether Hyperfine reports growth in Swoop system sales. Rising sales would show hospitals are adopting its bedside brain-diagnostic equipment, a potentially supportive backdrop for Ceribell’s hospital sales, but would not show that hospitals are using more seizure-monitoring EEG. Weak sales would mean Hyperfine’s system has not shown broad uptake; they would not establish weak demand for Ceribell.
